Dyadic International (DYAI) Exchange Rate Effect (2018 - 2026)
Dyadic International (DYAI) posted Exchange Rate Effect of -$633.0 for Q1 2026, down 88.39% sequentially from -$336.0 in Q4 2025, and down 140.34% YoY from $1569.0 in Q1 2025.
Dyadic International (DYAI) Exchange Rate Effect (2018 - 2026) Analysis & Trends
Dyadic International has reported Exchange Rate Effect for 9 years, with the latest figure at -$633.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 140.34% year-over-year to -$633.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$261.0 (up 89.86% YoY) and the FY2025 annual result came in at $1941.0, up 133.49% from the prior year.
- Exchange Rate Effect eased to -$633.0 in Q1 2026 per DYAI's latest filing, from -$336.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $1569.0 in Q1 2025 and troughed at -$22501.0 in Q4 2022.
- A 5-year average of -$3036.3 and a median of -$484.0 in 2023 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect slumped 656.12% in 2024, then soared 194.86% in 2025.
- Over 5 years, Exchange Rate Effect stood at -$22501.0 in 2022, then jumped by 104.79% to $1078.0 in 2023, then plunged by 656.12% to -$5995.0 in 2024, then soared by 94.4% to -$336.0 in 2025, then slumped by 88.39% to -$633.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$633.0, -$336.0, and -$416.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | - |
| 10 | Dyadic International | 19.89 Mn | 19.89 Mn | - | -633.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -633.00 |
| Mar 31, 2026 | -633.00 |
| Dec 31, 2025 | -336.00 |
| Dec 31, 2025 | -336.00 |
| Sep 30, 2025 | -416.00 |
| Sep 30, 2025 | -416.00 |
| Jun 30, 2025 | 1,124.00 |
| Jun 30, 2025 | 1,124.00 |
| Mar 31, 2025 | 1,569.00 |
| Mar 31, 2025 | 1,569.00 |
| Dec 31, 2024 | -5,995.00 |
| Dec 31, 2024 | -5,995.00 |
| Sep 30, 2024 | 1,250.00 |
| Sep 30, 2024 | 1,250.00 |
| Jun 30, 2024 | 603.00 |
| Jun 30, 2024 | 603.00 |
| Mar 31, 2024 | -1,654.00 |
| Mar 31, 2024 | -1,654.00 |
| Dec 31, 2023 | 1,078.00 |
| Dec 31, 2023 | 1,078.00 |